Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,360.00
+34.00 (2.56%)
At close: Aug 4, 2025, 3:30 PM KST
2.56%
Market Cap75.11B
Revenue (ttm)12.77B
Net Income (ttm)-8.28B
Shares Out56.05M
EPS (ttm)-152.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume159,075
Average Volume292,400
Open1,326.00
Previous Close1,326.00
Day's Range1,306.00 - 1,360.00
52-Week Range1,306.00 - 2,935.00
Beta0.65
RSI34.88
Earnings DateMar 14, 2025

About Six Flags Entertainment

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2023, Kangstem Biotech's revenue was 12.70 billion, a decrease of -22.06% compared to the previous year's 16.30 billion. Losses were -21.95 billion, 8.47% more than in 2022.

Financial Statements

News

There is no news available yet.